Cite
Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
MLA
Molly Maloy, et al. “Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.” Blood, vol. 134, Nov. 2019, p. 1603. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........5de8f79f6d430fc3d6cdb062fc193bad&authtype=sso&custid=ns315887.
APA
Molly Maloy, Michael Scordo, Yakup Batlevi, Maria Lia Palomba, Bianca Santomasso, Sergio Giralt, Gunjan L. Shah, Theresa A. Elko, Jason T Chan, Craig S. Sauter, Stephanie Lobaugh, Connie Lee Batlevi, Richard J. Lin, Elena Mead, Chelsea A Brooklyn, Beatriz Korc-Grodzicki, Ariela Noy, Parastoo B. Dahi, Sean M. Devlin, … Miguel-Angel Perales. (2019). Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood, 134, 1603.
Chicago
Molly Maloy, Michael Scordo, Yakup Batlevi, Maria Lia Palomba, Bianca Santomasso, Sergio Giralt, Gunjan L. Shah, et al. 2019. “Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.” Blood 134 (November): 1603. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........5de8f79f6d430fc3d6cdb062fc193bad&authtype=sso&custid=ns315887.